Ann Transl Med. 2015 Nov;3(20):304. doi: 10.3978/j.issn.2305-5839.2015.11.29.

Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas.

Annals of translational medicine

Meryem Aktan, Mehmet Koc, Gul Kanyilmaz

PMID: 26697464 PMCID: PMC4669324 DOI: 10.3978/j.issn.2305-5839.2015.11.29

Abstract

BACKGROUND: High grade gliomas often recur after initial treatment. Despite so many treatment options, there is no standard treatment for recurrent gliomas. The aim of this study is to offer survival following reirradiation (re-RT) using intensity-modulated radiation therapy (IMRT) with temozolomide in selected patients with recurrent high grade gliomas.

METHODS: We examined the medical records of 21 adult patients with recurrent high grade gliomas who were reirradiated with IMRT at the time of tumor recurrence or progression. Tumor recurrence was shown by gadolinium-enhanced magnetic resonance imaging (MRI) and diagnosis was established by pathology review. Statistical analyses were performed with SPSS version 18.0.1 using Cox regression analyses, log-rank test and Kaplan-Meier method.

RESULTS: Eighteen patients presented by localized recurrence, three patients with diffuse recurrence. Median radiotherapy (RT) dose was 54 Gy. About 81% patients received temozolomide with re-RT. The time interval between two courses RT was median 39.3 months (range, 9.6-140.8 months). The response was checked by MRI. About 24% patients achieved complete response (CR) and 29% patient partial response (PR). Stable disease (SD) was observed in 47% patients. Median follow-up time from diagnosis was 41.4 months (range, 16.6-145.4 months) and 12.3 months (range, 2-27.6 months) from re-RT. Median time to recurrence was 39.3 months (range, 9.6-140.8 months). Median survival after re-RT was 18 months for anaplastic astrocytoma (AA), 14.1 months for glioblastoma multiforme (GBM) (range, 11-17.2 months) (P=0.1) and 7.1 months for patients with Karnofsky performance status (KPS) <70 before re-RT and 17.4 months for KPS >70 (P=0.02).

CONCLUSIONS: re-RT is one of the treatment options for recurrent high grade gliomas and IMRT can be an effective treatment modality for recurrent high grade brain tumors with only mild side effects. Survival is better in patients with good performance status and in recurrent anaplastic tumors after re-RT.

Keywords: Glioma; glioblastoma; intensity modulated radiotherapy; reirradiation (re-RT); survival

References

1. Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
2. Neurology. 2001 Jul 24;57(2):340-2 - PubMed
3. Curr Oncol Rep. 2006 Jan;8(1):45-9 - PubMed
4. Neuro Oncol. 2013 Jul;15(7):930-5 - PubMed
5. Neuro Oncol. 1999 Oct;1(4):282-8 - PubMed
6. Radiother Oncol. 2001 May;59(2):127-37 - PubMed
7. CNS Oncol. 2014 Jul;3(4):257-65 - PubMed
8. Cancers (Basel). 2011 Oct 28;3(4):4061-89 - PubMed
9. Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49 - PubMed
10. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
11. J Neurooncol. 2015 Sep;124(2):215-21 - PubMed
12. Radiat Oncol. 2007 Jul 14;2:26 - PubMed
13. Neuro Oncol. 2008 Dec;10(6):1025-34 - PubMed
14. Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1350-60 - PubMed
15. Neuro Oncol. 2013 Jan;15(1):4-27 - PubMed
16. Cancer. 2008 May 1;112(9):2046-51 - PubMed
17. Cancer Control. 2003 Mar-Apr;10(2):109-14 - PubMed
18. Semin Radiat Oncol. 2014 Oct;24(4):289-98 - PubMed
19. Cancer Treat Rev. 2006 Aug;32(5):348-64 - PubMed
20. Neuro Oncol. 2014 Sep;16(9):1255-62 - PubMed
21. Am J Clin Oncol. 2002 Dec;25(6):606-11 - PubMed
22. Cancer Treat Rev. 2000 Dec;26(6):397-409 - PubMed
23. J Neurooncol. 2015 Nov;125(2):339-49 - PubMed
24. Neuro Oncol. 2013 Feb;15(2):242-50 - PubMed
25. J Clin Oncol. 2006 Mar 10;24(8):1273-80 - PubMed
26. Crit Rev Oncol Hematol. 2006 Dec;60(3):181-93 - PubMed
27. Ann Transl Med. 2014 May;2(5):44 - PubMed

Publication Types

• Journal Article